The POU4F2/Brn-3b transcription factor has been identified as a potentially novel regulator of key metabolic 22 processes. Loss of this protein in Brn-3b knockout (KO) mice causes profound hyperglycemia and insulin resistance 23 (IR), normally associated with type II diabetes (T2D), whilst Brn-3b is reduced in tissues taken from obese mice fed 24 on high-fat diets (HFD), which also develop hyperglycemia and IR. Furthermore, studies in C2C12 myocytes show 25 that Brn-3b mRNA and proteins are induced by glucose but inhibited by insulin, suggesting that this protein is itself 26 highly regulated in responsive cells. Analysis of differential gene expression in skeletal muscle from Brn-3b KO mice 27 showed changes in genes that are implicated in T2D such as increased glycogen synthase kinase-3 beta (GSK3β) and 28 reduced GLUT4 glucose transporter. The GLUT4 gene promoter contains multiple Brn-3b binding sites and is directly 29 transactivated by this transcription factor in co-transfection assays whereas chromatin immunoprecipitation (ChIP) 30 assays confirm that Brn-3b binds to this promoter, in-vivo. In addition, strong correlation between GLUT4 and Brn-3b 31 in Brn-3bKO tissues or in C2C12 cells strongly supports a close association between Brn-3b levels and GLUT4 32 expression. Since Brn-3b is regulated by metabolites and insulin, this may provide a mechanism for controlling key 33 genes that are required for normal metabolic processes in insulin-responsive tissues and its loss may contribute to 34 abnormal glucose uptake. 
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high Brn-3b expression in insulin responsive tissues such as skeletal muscle may suggests that persistent 124 hyperglycemia and insulin resistance in Brn-3b KO mutants are likely to be associated with defects in metabolically 125 active tissues rather than the pancreas, in which Brn-3b is not readily detected. 126 127 Brn-3b is reduced in insulin responsive tissues of WT mice fed on a diet with high saturated fat content: 128
Since loss of Brn-3b was associated with increased body weight and hyperglycemia, we considered if reduction of this 129 protein may be linked to diet induced obesity, which can also cause hyperglycemia and insulin resistance in rodent 130 models (38). To test this hypothesis, we generated and analysed a diet-induced obese mouse model in which WT mice, 131 fed on diet containing 60% saturated fat (HFD) for >12 weeks, were compared with control mice fed on normal diet 132 (ND). Most of the mice fed on HFD developed significant increase in BW when compared with age-matched controls 133 fed on ND. However, one animal fed on ND developed obesity, whereas one animal fed on HFD did not show 134 increased BW. Since these studies aimed to analyse the link between body weight and Brn-3b, these 2 mice were 135 excluded. At the end of these studies, GTT was undertaken on fasted mice to analyse blood glucose levels at baseline 136 (time 0) and then at 30, 60 and 120 min after administration of a glucose bolus. Although there were no significant 137 differences in blood glucose or serum insulin levels, at baseline between these groups (fig 2A) , differences were 138 detected after 120 min when animals fed on ND showed an expected drop in blood glucose and serum insulin, similar 139 to baseline levels. However, animals fed on HFD demonstrated significantly elevated blood glucose and this was 140 associated with increased serum insulin levels Fig 2A(ii +iii) , similar to the effect seen in Brn-3bKO mutants. 141
To examine potential links between changes in Brn-3b expression and development of pathophysiological effects in 142 these mice, we analysed for protein expression in insulin responsive tissues taken from mice fed on HFD or ND. 143
Analyses were carried out using skeletal muscle, which contributes to postprandial glucose uptake and adipose tissue, 144 which was considerably increased in animals fed on HFD. Fig 2B (i) shows protein levels in skeletal muscle and as 145 expected, Brn-3b(s) was highly expressed in tissues taken from ND fed mice but was significantly reduced in those 146 fed on HFD (ii). Adipose tissues expressed both Brn-3b isoforms but with higher levels of Brn-3b(l) detected in mice 147 fed on ND [ fig 2B ( iii)]. However, both isoforms were significantly reduced in tissues from HFD fed mice. Theseresults suggest that Brn-3b proteins are highly regulated in such metabolically active tissues and its reduction may 149 contribute to hyperglycemia observed in obese WT animals or in KO mutants. 150 151 Brn-3b expression is regulated by glucose and insulin in C2C12 myoblasts. 152
Since loss or reduction of Brn-3b was associated with high serum insulin and hyperglycemia, we next tested if Brn-3b 153 expression was affected by glucose and/or insulin in C2C12 myoblasts. Therefore, cells were either grown in medium 154 lacking glucose (NG); NG media supplemented with 25mmol glucose in the absence of insulin (NG-GLU); or with 155 added insulin (NG-GLU-INS). Control cells were grown in full growth medium (FGM). Fig 3A shows that Brn-3b 156 mRNA was reduced in cells grown in glucose-free medium and this was restored upon addition of 25 mmol glucose 157 (fig 4A) , whereas chronic insulin treatment (10nmol for 24h) down-regulated Brn-3b mRNA, although insulin had no 158 effect at early time points (1 or 4h) (data not shown). These results were confirmed by immunoblotting to analyse 159 changes in protein levels. Although both Brn-3b isoforms were detectable in these cells, Brn-3b(s) was more abundant 160 than Brn-3b(l) (fig 4B) , which is similar to previous data showing that was the primary isoform in skeletal 161 muscle [ fig 2A( ii)]. Cells that were grown in NG medium had reduced levels of both proteins, with Brn-3b(l) being 162 undetectable. Brn-3b(s) levels for restored and sustained by adding glucose to the NS medium, whereas addition of 163 insulin caused reduction of both Brn-3b isoforms. 164
165
Since Brn-3b expression was stimulated by glucose but reduced by insulin treatment, we next tested if these effects 166 were mediated at the level of transcription of the Brn-3b promoter. Therefore, C2C12 myoblasts were transfected with 167
Brn-3b reporter construct, then transferred into different growth conditions. Cells were harvested after 24h and dual 168 luciferase assays were used to measure promoter activity. Fig 3C shows that Brn-3b promoter activity was 169 significantly repressed when cells were grown in medium lacking glucose (NG) compared with FGM, whereas 170 addition of 25mM glucose was sufficient to increase promoter activity (>60 fold) compared with NG. However the 171 promoter was repressed by insulin. These results suggest that Brn-3b expression is highly regulated by glucose and 172 insulin in skeletal muscle. 173
175
Gene expression changes associated with loss of Brn-3b in skeletal muscle:muscle taken from mutant mice or age-matched WT littermates(see methods). Table 1 shows a selection of genes that 179 were either over-expressed or under-expressed in Brn-3bKO mutants compared with WT controls. To validate 180 changes in selected genes, qRT-PCR was carried out using RNA from skeletal muscle taken from independent Brn-181 3bKO or WT mice. Figure 4 shows that statistically significant changes were reproduced for glycogen synthase kinase 182 3 beta (GSK3β) mRNA, which was increased in Brn-3b KO mutants, whereas angiotensin-1 converting enzyme 183 (ACE) and the solute carrier family 4 glucose transporter (GLUT4) were both reduced in mutant tissue. However, the 184 expected changes in other genes were not significant or reproducible suggesting that GSK3β, ACE and GLUT4 may 185 be closely linked to Brn-3b expression. 186
Brn-3b binds to and activates the insulin-responsive glucose transporter, GLUT4: 187
The profound dysfunction in glucose handling observed in Brn-3b KO mutants was similar to impaired glucose 188 response and insulin resistance reported for GLUT4 (+/-) or (-/-) fig 5A) . These were clustered in two regions that were either proximal to the coding sequence 192 (indicated by p1 and p2) and distal sites (p3-p4). Therefore we tested if Brn-3b regulated transcription of this 193 promoter, co-transfection studies were carried out, in which the GLUT4 luciferase reporter was co-transfected with 194 different concentrations of Brn-3b expression vectors, into C2C12 cells. Results of the luciferase assays showed that at 195 1:1 ratio, Brn-3b transactivated the promoter by >4 fold but promoter activity was significantly enhanced (>12 fold) 196 when Brn-3b was increased to 2:1 (Fig 5B) , confirming that Brn-3b does indeed, regulate GLUT4 promoter activity. 197
Since there were multiple potential binding sites spanning relatively large regions of the GLUT4 promoter, it was not 198 feasible to undertake site directed mutagenesis to identify specific site(s) that were required for Brn-3b-mediated 199 promoter activity. Therefore, to test if Brn-3b binds directly to the GLUT4 promoter in-vivo, in intact cells, we carried 200 out chromatin immunoprecipitation (ChIP) assays (26), in which Brn-3b Abs were used to immunoprecipitate the 201 protein bound to chromatin in intact C2C12 cells. GAPDH antibody was used as a negative control for binding 202 specificity. ChIP DNA isolated using Brn-3b Ab or GAPDH Ab control were used for PCR with primers designed to 203 amplify the two regions of GLUT4 promoter that were enriched for Brn-3b binding sites i.e. the proximal sites 204 (primers 1+2) or distal sites (primers 3+4) and the PCR products were resolved and 2% agarose gel. As shown in Figsample and ChIP DNA immunoprecipitated with Brn-3b Ab but not control Ab. However, although primers 3+4 gave 207 rise to ~350 bp products with the input DNA, no significant bands were produced when using the Brn-3b ChIP DNA. 208
These results suggest that Brn-3b binds directly to one or more of the sites in the proximal GLUT4 promoter to 209 activate gene expression. 210
To determine whether Brn-3b was necessary for maximal transcription of this gene, we next analysed for changes in 211 GLUT4 mRNA in insulin-responsive tissues such as skeletal muscle and adipose tissue, taken from mutants or age-212 matched WT controls. Therefore, RNA from Brn-3b KO or WT tissues was used for cDNA synthesis and 213 quantification of GLUT4 transcripts using qRT-PCR whereas whole-cell protein extracts were used for immunoblots. 214
Fig 5D (i) shows that GLUT4 mRNA was significantly lower in skeletal muscle taken from Brn-3b KO mutants when 215 compared with levels in WT tissues, confirming that Brn-3b is necessary for transcription of this gene. To test if 216 reduced GLUT4 transcripts in Brn-3b KO mutants also affected protein levels, immunoblotting was carried out using 217 total cellular protein, extracted from insulin-responsive tissues from Brn-3b KO and WT controls. The representative 218 immunoblots shown in Fig 5D (ii) shows that the GLUT4 protein was reduced in Brn-3b KO adipose tissues, with ~ 219
50% less protein, when compared with controls (iii). 220
We next tested if overexpressing Brn-3b affected basal GLUT4 protein levels in myoblasts by transfecting C2C12 221 cells with an expression vector containing Brn-3b cDNA (at 1 µg or 2 µg). Untransfected control cells (C) or cells 222 transfected with the empty expression vector (V) were used as controls and after 48 hours, protein extracts from 223 transfected cells were used for immunoblotting to analyse changes in GLUT4 and Brn-3b expression. Fig 5E shows athe development and progression of such diseases but the factors to control such changes are not fully understood (36) . 235 Hyperglycemia, insulin resistance and T2D are set to rise, in line with a predicted global obesity epidemic, which is 236 linked to dietary and lifestyle changes (11; 25; 36) . Therefore, it is important to understand the molecular mechanisms 237 that drive pathological changes since this may help to identify strategies that could be used to block or reverse tissue 238 damage, thereby minimising morbidity and mortality. 239
In this regard, we have identified Brn-3b as a novel regulator of glucose homeostasis. The first evidence suggesting 240 that this transcription factor may be involved in regulating metabolic processes, was inferred from microarray 241 analysis, which showed that Brn-3b was significantly altered in skeletal muscle taken from individuals with high or 242 low insulin sensitivity, following endurance training (37). Results from our studies have shown that Brn-3b protein is 243 expressed in insulin-responsive tissues such as skeletal muscle, adipose tissue as well as in liver, but has not been 244 detected in the pancreas. Furthermore, higher body weight in constitutive Brn-3b KO mice are associated with 245 increased fat deposition in the abdominal cavity, despite no statistically significant changes in body length or 246 differences in calorie consumption, when compared with control mice. Brn-3b KO mutants also developed persistent 247 hyperglycemia, in the presence of high serum insulin levels, suggesting that the pancreas continues to produce insulin 248 and high blood glucose may be linked to defects in insulin responsiveness and/or glucose uptake in tissues such as 249 skeletal muscle and adipose tissues. In line with this, Brn-3b expression is also reduced in skeletal muscle and adipose 250 tissues taken from WT mice that develop obesity and hyperglycemia/insulin resistance after being fed on a high 251 saturated fat diet. These results suggest that Brn-3b is dynamically regulated in such tissues and that the metabolic 252 dysfunction in constitutive KO mutants may result from direct loss of this transcription factor in insulin responsive 253
tissues. 254
Two distinct Brn-3b isoforms have previously been described (3; 8) and we have shown that Brn-3b(s) is the 255 predominant isoform in skeletal muscle, whereas Brn-3b(l) is more abundant in liver and adipose tissues. Moreover 256 both isoforms are regulated in response to high-fat diet. Although the functions of these distinct isoforms are still to be 257 elucidated, both proteins can be regulated by similar signals but can also regulate each other 's expression (8; 17) . 258
Therefore, it will be interesting to investigate potential tissue-specific effects for distinct Brn-3b isoforms in insulin 259 responsive tissues, in later studies. 260
These results have provided evidence to support potential roles for the Brn-3b transcription factor in controllingbe regulated by insulin and metabolites such as glucose. In this regard, Brn-3b mRNA and proteins are reduced in 263 cells grown in low glucose media or in the presence of insulin but can be restored by addition of physiological levels 264 of glucose (25 mM). These effects are likely to be mediated at the level of transcription since low glucose or insulin 265 can repress the Brn-3b promoter, whereas addition of glucose strongly stimulated promoter activity. Such tight 266 regulation of Brn-3b by insulin and glucose indicate that this transcription factor will have important role(s) for 267 regulating genes associated with glucose uptake. 268
In line with this, analysis of differential gene expression in skeletal muscle taken from Brn-3bKO and WT mice have 269 identified changes in key genes that are associated with metabolic processes. For example, increased GSK3β in Brn-270 3b KO tissues may contribute to insulin resistance by phosphorylating and inhibiting key molecules such as glycogen 271 synthase and insulin receptor substrate proteins and importantly, elevated GSK3β has been detected in skeletal muscle 272 of patients with T2D (10; 16; 30). On the other hand, reduced GLUT4 in tissues taken from Brn-3b KO may underlie 273 the glucose intolerance detected in these mutants since Brn-3b directly regulates transcription of GLUT4 receptor. 274
Multiple potential Brn-3b binding sites have been identified by bioinformatic analysis and reporter assays confirm that 275 increasing exogenous Brn-3b can strongly transactivate the GLUT4 promoter in C2C12 cells. The presence of 276 multiple sites, clustered in 2 regions of the GLUT4 promoter, meant that it has not been possible to use site directed 277 mutagenesis to identify the specific sequence(s) required for Brn-3b binding and promoter activation. However, ChIP 278 analysis has conclusively demonstrated that Brn-3b binds directly to the proximal sites in the GLUT4 promoter, in-279 vivo, in intact myoblast cells. There is also strong evidence for significant correlation between Brn-3b and GLUT4 280 expression from in-vivo and in vitro studies. Thus, GLUT4 mRNA and protein are reduced in insulin responsive 281 tissues (skeletal muscle and adipose), taken from Brn-3b KO mutant and altered Brn-3b correlate well with GLUT4 282 expression in C2C12 myoblasts, grown under different conditions. In addition, overexpressing Brn-3b in C2C12 cells 283 is sufficient to increase basal GLUT4 levels. 284
These findings strongly suggest that Brn-3b may be a key regulator of GLUT4 expression in insulin responsive tissues 285 and that loss of this receptor may contribute, in part, to hyperglycemia and insulin resistance observed in Brn-3b KO 286 mutants or in obese mice with reduced Brn-3b expression. The GLUT4 transporter is important for insulin-mediated 287 glucose uptake in adipose tissues and skeletal muscle, which accounts for majority of post-prandial glucose utilisation 288 (27). Although GLUT4 translocation from intracellular vesicles to the cell membrane is an important mechanism for 289 regulating glucose uptake, changes in expression levels have also been implicated in inefficient glucose utilization. 290 32; 35) . Although the relevance of reduced GLUT4 in humans with non-insulin-dependent T2D has been 293 brought into question more recently (31), the clear correlation between Brn-3b and GLUT4 expression in insulin 294 responsive tissues, in these studies, strongly suggest that this transcription factor will be important for regulating the 295 expression of this glucose transporter in different tissues. However, GLUT4 is likely to be one of multiple target genes 296 that are regulated by the Brn-3b transcription factor in insulin responsive tissue that give rise to the complex 297 phenotypes seen in the constitutive KO mutants. 298
Thus, Brn-3b represents a novel and important regulator of metabolic processes in insulin responsive tissues. 299
However, since its expression is also controlled by circulating levels of metabolites and insulin, this transcription 300 factor may act as part of a feedback loop that maintains glucose homoeostasis, under normal conditions. Glucose Tolerance Tests (GTT) and Serum Insulin measurement: For GTT, experimental animals were fasted for 319 12 hours and baseline blood glucose was evaluated using a glucometer. Glucose bolus (2mg glucose/g BW) was 320 administered by intraperitoneal injection and blood glucose recorded after 15, 30, 60 and 120 min. For serum insulin 321 measurements, whole blood was collected from saphenous vein at the start and end of experiments into serum 322 separator tubes [BD Microtainer® (Becton-Dickinson, Franklin Lakes, NJ, USA)]. Serum insulin levels were 323 measured using Mercodia Mouse Insulin ELISA kit, Upsalla, Sweden). 324
Calorie consumption: Calorie consumption was calculated by monitoring dietary intake and then using the known 325 caloric value of the feed to calculate intake. Briefly mice were housed in separate cages and the chow was weighed at 326 the start of experiments and this was repeated at the end of each week, before topping up or replacing the feed. This 327 was also measured if it was deemed necessary to top up on at other times. The differences in weight (grams) of the 328 feed at the start and end of the week were multiplied by the known caloric value (5.1 kcal/gram) to calculate calorie 329 consumption per week for each mouse. The mean and standard error of each group (n>5) were used to determine 330 differences in calorie consumption over time. 331
Cell culture and treatments: Skeletal muscle satellite cell-derived C2C12 myoblasts were maintained in full growth 332
medium (FGM) [Dulbecco's Modified Eagle's Medium (DMEM); 10% foetal bovine serum (FBS); 1% 333
penicillin/streptomycin], grown in 5% CO2 at 37°C. Cells plated onto 6-well (5× 105/well) or 12-well (105/well) 334 culture dishes were transfected or treated as specified. Free fatty acids (FFA) -unsaturated long chain oleic acid and 335 saturated palmitic acid were dissolved in ethanol and used to treat cells. Transfections was carried out using Fugene TM 336 (Promega, Hampshire, UK) as previously described (6; 33) and reporter assays using the Dual Luciferase Reporter 337 Assay System (Promega, Hampshire, UK). 338
RNA extraction, cDNA synthesis, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR): 339
Tissues homogenized in liquid nitrogen were resuspended in TRIZOL® (Invitrogen); C2C12 cells were harvested in 340
Trizol then processed according to the manufacturer's protocol. DNAse1 treated RNA was used for cDNA synthesis 341 (RNA Superscript™II RT) (Invitrogen,Paisley,UK). QRT-PCR was performed on Opticon 2 DNA engine thermal 342 cycler (BioRad, UK), using SYBR Green master mix (Qiagen, UK) and Brn-3b primers (forwardPCR array analysis: cDNA from Brn-3b KO skeletal muscle and WT controls (see above) were used to screen the 347 Mouse Diabetes RT² (SAB BioSciences, Qiagen, West Sussex, UK), which facilities the screening of 84 genes 348 associated with onset, development and progression of diabetes. Quantitative PCR was undertaken according to the 349 manufacturers' protocol using the Opticon 2 DNA thermal cycler and analysis done using PCR Array Data Analysis 350
Software https://www.qiagen.com/gb/products/genes and pathways/data-analysis. diet (HFD). Values were normalised to β-tubulin in corresponding samples and represent the mean and standard error 503 from four independent animals. * Indicates statistically significant reduction (iii) Brn-3b expression in in Brn-3b 504 protein in tissues taken from animals fed on HFD compared with ND as determined by t-test (n>3). 505 promoter reporter construct (2:1 or 4:1) into C2C12 cells. Values were equalized with internal control, renilla 533 luciferase activity and expressed relative to the promoter only (set at 1). The data shown represent mean +/-SD from 534 at least 3 independent experiments. C. PCR products obtained when using ChIP DNA immunoprecipitated with Brn-535 3b or GAPDH antibody (negative control). Primers 1-2 amplified ~500 bp proximal PCR product, whereas primers 3-536 4 were designed to amplify a distal region of the promoter. D. (i) Results of qRT-PCR showing changes in GLUT4 537 mRNA levels in skeletal muscle prepared from Brn-3bKO mutant mice (n = 5) when compared with WT littermate 538 controls (n = 4). Variability in total RNA from different tissues were equalised using the housekeeping gene, GAPDH. Fig 2:Reduced Brn-3b expression in insulin-responsive tissues in animals fed on a high-fat diet correlates with (iii) p= 0.01 *
